- Home
- PLX
as 12-20-2024 4:00pm EST
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
| Founded: | 1993 | Country: | Israel |
| Employees: | N/A | City: | HACKENSACK |
| Market Cap: | 132.5M | IPO Year: | 1998 |
| Target Price: | N/A | AVG Volume (30 days): | 382.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.82 - $1.90 | Next Earning Date: | 11-14-2024 |
| Revenue: | $45,667,000 | Revenue Growth: | -28.22% |
| Revenue Growth (this year): | -17.21% | Revenue Growth (next year): | 88.94% |
Latest Protalix BioTherapeutics Inc. (DE) News
PLX Breaking Stock News: Dive into PLX Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
12 days ago
EMA validates Chiesi and Protalix’s dose variation for Fabry disease
Simply Wall St.
12 days ago
Promising US Penny Stocks To Watch In December 2024
PR Newswire
13 days ago
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
Zacks Small Cap Research
a month ago
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
GuruFocus.com
a month ago
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
Associated Press Finance
a month ago
Protalix: Q3 Earnings Snapshot
PR Newswire
a month ago
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
PR Newswire
a month ago
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024
Compare PLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLX Protalix BioTherapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.